FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely oncology and can be used for treatment of inflammatory breast cancer. The therapy is implemented as follows. The preoperative therapy is combined with hypodermical introduction of prescribed recombinant tumour necrosis α-factor thymosin-α1 in a dose 200000 ME on the day of chemotherapy 30 minutes prior to introduction of cytostatic agents and 4 days after chemotherapy.
EFFECT: application of the invention allows ensuring tumour regress and reducing therapeutic toxicity due to combined cytostatic agents and recombinant tumour necrosis α-factor thymosin-α1.
2 ex
Authors
Dates
2009-08-20—Published
2008-05-29—Filed